The Emerging Role of Estrogen Receptor 1 (ESR1) Mutations and Circulating Tumor DNA Testing in Patients With Metastatic Breast Cancer

This workshop underscores the value of early testing for biomarkers of disease progression in patients with estrogen receptor-positive metastatic breast cancer. ESR1 mutations have been identified as influential factors that can lead to loss of aromatase inhibitor activity and clinical progression. Serial testing of ESR1 mutations may proactively detect endocrine therapy resistance before radiologic progression occurs.